Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.
Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.
Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.
Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.
OptimizeRx Corp (Nasdaq: OPRX) CEO Will Febbo will present at the J.P. Morgan Healthcare Conference on January 12, 2023. The company has reported winning six deals leveraging AI and Real World Evidence capabilities, anticipating over 100% year-over-year growth in RWE-related sales. OPRX emphasizes its extensive network, reaching over 60% of active prescribers, aiming to enhance patient outcomes through innovative technology. The firm remains committed to digital engagement in healthcare, striving for a shift from tactical to solution-based selling while maintaining strong partnerships with major pharma brands.
OptimizeRx Corp (Nasdaq: OPRX), known for its point-of-care technology solutions, will participate in several investor conferences. Key events include the Piper Sandler 34th Annual Healthcare Conference in New York City from November 29 to December 1, 2022, and the J.P. Morgan Healthcare Conference in San Francisco from January 9 to January 12, 2023. Management is available for one-on-one meetings during these events. OptimizeRx aims to enhance patient care by connecting healthcare providers and patients through innovative technology.
OptimizeRx Corp. (OPRX) reported Q3 2022 revenue of $15.1 million, a 6% year-over-year decline but an 8% quarter-over-quarter increase. Gross profit rose 4% to $9.4 million, with gross margins improving from 56% to 62%. The company generated $7.9 million in cash flow from operations in the first nine months of 2022 and has repurchased 1.1 million shares at an average price of $16.70. The 2022 revenue outlook remains between $62 million and $68 million, indicating 1% to 11% growth.
OptimizeRx Corp (Nasdaq: OPRX) announced its third annual Innovate4Outcomes event, set for December 1, 2022. Co-sponsored with Melinta Therapeutics, this virtual event will bring together healthcare providers and industry professionals to tackle Antimicrobial Resistance (AMR), identified by the WHO as a major global health challenge. Participants will collaborate in teams to devise solutions, with the winning concept receiving support for further development. This initiative underscores the company’s commitment to enhancing therapy access and adherence amid pressing healthcare issues.
OptimizeRx Corp (Nasdaq: OPRX) announced a conference call scheduled for November 8, 2022, at 4:30 p.m. ET to discuss its third-quarter financial results for the period ended September 30, 2022. The call will be hosted by OptimizeRx management, followed by a question-and-answer session. Investors can access details via a webcast or through toll-free and international numbers. This call follows the release of the financial results, which will be issued beforehand.
OptimizeRx specializes in point-of-care technology solutions that facilitate patient therapy adherence.
OptimizeRx (Nasdaq: OPRX) has announced successful results from a program utilizing its AI/real-world evidence technology to improve patient identification for specialty therapy. The initiative showed a 28% increase in therapy initiation per healthcare provider and identified 33% of new patients accurately. Key features of the program included earlier patient identification and data-driven qualification, enhancing communication between healthcare providers and patients. This advancement aims to address challenges in misdiagnosis and treatment delays for complex diseases.
OptimizeRx Corp (Nasdaq: OPRX) has announced a renewed exclusive partnership with Therapy Brands, extending their collaboration that began in 2019. This agreement enhances the access to NewCrop's ePrescribing platform, which supports healthcare professionals (HCPs) through OptimizeRx's Therapy Initiation and Persistence Platform. Both companies aim to streamline workflows and improve patient treatment information accessibility. The partnership reinforces OptimizeRx's position in delivering point-of-care solutions that help patients start and maintain their therapy effectively.
OptimizeRx Corp (Nasdaq: OPRX) announced its participation in three upcoming conferences this September. Management will attend the R.W. Baird Healthcare Conference in New York City on September 13, the Lake Street BIG6 Investor Conference on September 14, and the LifeSci Health Tech Symposium virtually on September 21. Presentations will cover the company's innovative point-of-care technology solutions aimed at helping patients manage their therapies. Interested parties can request in-person meetings through designated contacts.
OptimizeRx Corp (Nasdaq: OPRX) reports a successful case study highlighting its patent-pending real-world evidence solution, which identifies healthcare providers (HCPs) with patients at risk of non-adherence due to unexpected costs. The program, launched with a major pharmaceutical manufacturer, achieved over 200% growth in identified HCPs, leading to more than 46,000 additional prescriptions. The solution demonstrated a +6:1 return on investment and helped 27% of targeted HCPs enroll new patients. This advancement in predictive analytics showcases the company's ability to improve patient care and support HCPs effectively.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 3% increase in revenue for Q2 2022, totaling $14.0 million, compared to $13.6 million in Q2 2021, largely due to new customer and program launches. Gross profit rose 12% year-over-year to $9.0 million. However, the company experienced a GAAP net loss of $3.9 million or ($0.21 per share). Cash and cash equivalents increased to $87.4 million. The updated 2022 revenue outlook anticipates $62 million to $68 million, marking 1% to 11% growth from 2021.
